Stemness subtypes in lower-grade glioma with prognostic biomarkers, tumor microenvironment, and treatment response

• Published in: Scientific reports 2024-06, Vol.14 (1), p.14758-22, Article 14758
• Main Authors: Ye, Shengda, Yang, Bin, Yang, Liu, Wei, Wei, Fu, Mingyue, Yan, Yu, Wang, Bo, Li, Xiang, Liang, Chen, Zhao, Wenyuan
• Format: Article
• Language: English
• Subjects: 631/67; 631/80; Bioinformatics; Biomarkers, Tumor - genetics; Brain Neoplasms - genetics; Brain Neoplasms - mortality; Brain Neoplasms - pathology; Brain Neoplasms - therapy; Cell Line, Tumor; Cell Proliferation; Experimental methods; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Glioma - genetics; Glioma - pathology; Glioma - therapy; Glioma cells; Humanities and Social Sciences; Humans; Immunosuppression; Immunotherapy; Leukocyte migration; Lower grade glioma; Macrophages; Male; Mast cells; Medical prognosis; multidisciplinary; Neoplasm Grading; Neoplastic Stem Cells - metabolism; Neoplastic Stem Cells - pathology; Nomogram; Phenotypes; Prognosis; Regression analysis; Science; Science (multidisciplinary); Stem cell; Stem cells; Tumor microenvironment; Tumor Microenvironment - genetics; Tumor Microenvironment - immunology
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-65717-7

Our research endeavors are directed towards unraveling the stem cell characteristics of lower-grade glioma patients, with the ultimate goal of formulating personalized treatment strategies. We computed enrichment stemness scores and performed consensus clustering to categorize phenotypes. Subsequently, we constructed a prognostic risk model using weighted gene correlation network analysis (WGCNA), random survival forest regression analysis as well as full subset regression analysis. To validate the expression differences of key genes, we employed experimental methods such as quantitative Polymerase Chain Reaction (qPCR) and assessed cell line proliferation, migration, and invasion. Three subtypes were assigned to patients diagnosed with LGG. Notably, Cluster 2 (C2), exhibiting the poorest survival outcomes, manifested characteristics indicative of the subtype characterized by immunosuppression. This was marked by elevated levels of M1 macrophages, activated mast cells, along with higher immune and stromal scores. Four hub genes—CDCA8, ORC1, DLGAP5, and SMC4—were identified and validated through cell experiments and qPCR. Subsequently, these validated genes were utilized to construct a stemness risk signature. Which revealed that Lower-Grade Glioma (LGG) patients with lower scores were more inclined to demonstrate favorable responses to immune therapy. Our study illuminates the stemness characteristics of gliomas, which lays the foundation for developing therapeutic approaches targeting CSCs and enhancing the efficacy of current immunotherapies. By identifying the stemness subtype and its correlation with prognosis and TME patterns in glioma patients, we aim to advance the development of personalized treatments, enhancing the ability to predict and improve overall patient prognosis.